STING1 and neoplasm: For example, the combination of programmeddeath (PD)-1 blocker and a STING agonist almost fully inhibited thesolid tumor that was insensitive to single-agent treatment in a mousemodel.53 In the past few years, severalsynthetic compounds with more advantageous pharmacokinetic propertieswere also developed.50,54−56 To our knowledge,BDW568 is the first STING agonist that critically depends on residueA230 in STING.